Cantor Fitzgerald Initiates Coverage On Sagimet Biosciences with Overweight Rating, Announces Price Target of $10.71
Benzinga Newsdesk 1 month ago
Analyst RatingsNewsInitiationPrice Target
Cantor Fitzgerald analyst Yanni Souroutzidis initiates coverage on Sagimet Biosciences (NASDAQ:SGMT) with a Overweight rating and announces Price Target of $10.71.
Cantor Fitzgerald analyst Yanni Souroutzidis initiates coverage on Sagimet Biosciences (NASDAQ:SGMT) with a Overweight rating and announces Price Target of $10.71.